Flanvotumab Explained

Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma.[1] It targets TYRP1.[2]

Flanvotumab was developed by ImClone Systems, now owned by Eli Lilly.

Notes and References

  1. Web site: Statement On A Nonproprietary Name Adopted By The USAN Council: Flanvotumab. American Medical Association.
  2. Web site: Flanvotumab . Adis Insight . Springer Nature Switzerland AG .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Flanvotumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.